Spark Therapeutics Inc. has presented a proprietary adeno-associated viral (AAV) vector expressing an artificial miRNA targeting human α-synuclein (α-Syn) mRNA. Accumulation of misfolded and insoluble ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback